Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-03-20EMA Withdrawn: Pregabalin Zentiva k.s. (pregabalin) — Zentiva k.s.
The EMA withdrew pregabalin Zentiva k.s. from the market (Zentiva k.s.) with the therapeutic areas including anxiety disorders, neuralgia, a…
-
FDA approval · 2023-03-17FDA Approved: GABAPENTIN — Supplemental Application (TIME CAP LABORATORIES, INC)
FDA approved a supplemental application for gabapentin by Time Cap Laboratories, Inc., resulting in an approved update to the product's regu…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures [Phase 1, Phase 2]
A dose-ranging pilot study evaluating intracerebroventricular delivery of valproate in temporal seizures completed phases 1 and 2.
-
FDA approval · 2023-03-14FDA Approved: OXCARBAZEPINE — Supplemental Application (EPIC PHARMA, LLC)
The FDA approved a supplemental application for oxcarbazepine filed by Epic Pharma, LLC.
-
FDA approval · 2023-03-10FDA Approved: TOPIRAMATE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's original application for topiramate, making a generic version of the anti-seizure and migraine-prophylaxis medication av…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-08FDA Approved: TOPIRAMATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for Topiramate from Aurobindo Pharma Limited, confirming regulatory clearance for its generic Topi…
-
FDA approval · 2023-03-08FDA Approved: ZONISAMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Zonisamide from Aurobindo Pharma Limited (ANDA077645). The approval pertains to changes to the g…
-
FDA approval · 2023-03-07FDA Approved: TOPIRAMATE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for Topiramate submitted by NorthStar RxLLC. The approval indicates changes to the existing prod…
-
FDA approval · 2023-03-03FDA Approved: TIAGABINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for tiagabine hydrochloride from Teva Pharmaceuticals USA, Inc., indicating a labeling-related regul…
-
FDA approval · 2023-03-03FDA Approved: LEVETIRACETAM IN SODIUM CHLORIDE — Supplemental Application (Nexus Pharmaceuticals LLC)
FDA approved a supplemental application for levetiracetam in sodium chloride from Nexus Pharmaceuticals LLC to market a generic injectable f…
-
FDA approval · 2023-03-02FDA Approved: CARBAMAZEPINE ER — Original Application (Epic Pharma, LLC)
FDA approves the first original-application generic Carbamazepine ER from Epic Pharma, LLC under ANDA 216235. This extended-release formulat…
-
FDA approval · 2023-03-01FDA Approved: OXCARBAZEPINE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for oxcarbazepine filed by Amneal Pharmaceuticals LLC.
-
FDA approval · 2023-03-01FDA Approved: TOPIRAMATE — Original Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s original ANDA for a generic Topiramate product.
-
FDA approval · 2023-02-24FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote Sprinkles (divalproex sodium) submitted by AbbVie Inc.
-
FDA approval · 2023-02-24FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie, expanding the NDA with additional regul…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome [Phase 2]
Phase 2 trial update for ataluren in nonsense mutation-related CDKL5 and Dravet syndrome (epilepsy) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-10Clinical Trial Update: Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders [Phase 2, Phase 3]
Phase 2/3 clinical trial investigating DHA for treatment-refractory epilepsy has been terminated.
-
FDA approval · 2023-02-09FDA Approved: LACOSAMIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original generic application for lacosamide by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2023-02-08FDA Approved: DIAZEPAM — Supplemental Application (Natco Pharma USA LLC)
FDA approved Natco Pharma USA LLC's supplemental application for Diazepam (generic) under ANDA210363. This approval advances the generic Dia…
-
FDA approval · 2023-02-08FDA Approved: DIAZEPAM — Supplemental Application (Natco Pharma USA LLC)
FDA approves a supplemental application for Diazepam by Natco Pharma USA LLC, approving a supplemental change to the generic diazepam produc…
-
FDA approval · 2023-02-06FDA Approved: LACOSAMIDE — Original Application (Kanchan Healthcare Inc)
FDA approved a generic lacosamide product under ANDA216461, produced by Kanchan Healthcare Inc. This adds a generic option for lacosamide in…
-
CLINICAL_TRIALS withdrawal · 2023-02-02Clinical Trial Update: Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline [Phase 4]
Phase 4 trial comparing pregabalin to sertraline for anxiety in epilepsy patients was withdrawn.
-
FDA approval · 2023-01-31FDA Approved: LEVETIRACETAM — Original Application (Hp Halden Pharma AS)
FDA approved the original application for Levetiracetam (Hp Halden Pharma AS), a generic formulation used to treat epilepsy.
-
FDA approval · 2023-01-25FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approves a supplemental application for divalproex sodium submitted by Ajanta Pharma USA Inc.
-
FDA approval · 2023-01-23FDA Approved: ACETAZOLAMIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Acetazolamide (generic) submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals In…